Department of Internal Medicine, University of Ankara, İbni Sina Hospital, Ankara, Turkey.
Department of Endocrinology and Metabolism, University of Ankara, İbni Sina Hospital, Ankara, Turkey.
Clin Endocrinol (Oxf). 2017 Nov;87(5):459-465. doi: 10.1111/cen.13418. Epub 2017 Aug 9.
Symptomatic primary hyperparathyroidism (PHPT) is thought to be related to increased cardiovascular morbidity and mortality. In our study, we aimed to investigate endothelial dysfunction and markers of subclinical atherosclerosis in patients with PHPT. Also we aimed to demonstrate the effect of vitamin D supplementation on these parameters.
Twenty-nine patients followed by medical treatment (A), 25 preoperative (B) and 23 postoperative patients with PHPT (C), and 26 normocalcaemic subjects (D) were included. Groups were assessed by measurements of flow-mediated dilation (FMD), carotid intima-media thickness (CIMT), serum levels of sCD40L, high-sensitivity CRP (hs-CRP) and interleukin-8 (IL-8). Thirteen patients with low levels of 25-hydroxy-vitamin D (25OHD) in the medical treatment group were assessed before and 3 months after vitamin D replacement.
The median FMD was 5% in group A, 5.1% in group B, 7.6% in group C and 7.7% in group D. The FMD measurement in group A was significantly lower than groups C and D (P=.02) and was similar to the FMD measurement in group B. FMD measurements of group B were not significantly lower than groups C and D. In 13 patients with low 25OHD in group A, the median FMD increased to 7.07% from 4.71% after vitamin D replacement (P=.02).
Flow-mediated dilation was impaired in patients with PHPT, particularly in the medically observed group. Vitamin D supplementation seems to provide improvements in FMD in medically observed PHPT patients with low 25OHD levels, and this was the novel observation of our study.
有症状的原发性甲状旁腺功能亢进症(PHPT)被认为与心血管发病率和死亡率增加有关。在我们的研究中,我们旨在研究 PHPT 患者的内皮功能障碍和亚临床动脉粥样硬化标志物。我们还旨在证明维生素 D 补充对这些参数的影响。
29 例接受药物治疗的患者(A 组)、25 例术前(B 组)和 23 例术后 PHPT 患者(C 组)以及 26 例血钙正常的受试者(D 组)。通过测量血流介导的扩张(FMD)、颈动脉内膜中层厚度(CIMT)、血清可溶性 CD40L(sCD40L)、高敏 C 反应蛋白(hs-CRP)和白细胞介素-8(IL-8)水平来评估各组。在药物治疗组中,13 例 25-羟维生素 D(25OHD)水平低的患者在维生素 D 替代治疗前和 3 个月后进行评估。
A 组的 FMD 中位数为 5%,B 组为 5.1%,C 组为 7.6%,D 组为 7.7%。A 组的 FMD 测量值明显低于 C 组和 D 组(P=.02),与 B 组的 FMD 测量值相似。B 组的 FMD 测量值与 C 组和 D 组无显著差异。在 A 组中 13 例 25OHD 水平低的患者中,维生素 D 替代治疗后 FMD 中位数从 4.71%增加到 7.07%(P=.02)。
PHPT 患者的血流介导扩张受损,尤其是在接受药物治疗的患者中。维生素 D 补充似乎可改善低 25OHD 水平的药物治疗 PHPT 患者的 FMD,这是我们研究的新发现。